## Patrick Micke

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7760432/publications.pdf

Version: 2024-02-01

		87723		48187
108	8,896	38		88
papers	citations	h-index		g-index
			. '	
112	112	112		16746
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	A pathology atlas of the human cancer transcriptome. Science, 2017, 357, .	6.0	2,570
2	The protein expression profile of ACE2 in human tissues. Molecular Systems Biology, 2020, 16, e9610.	3.2	769
3	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9020-9029.	3.3	372
4	Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer, 2004, 45, S163-S175.	0.9	297
5	Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation. Clinical Cancer Research, 2013, 19, 194-204.	3.2	293
6	A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin <sup>îº</sup> C as a Compatible Prognostic Marker in Human Solid Tumors. Clinical Cancer Research, 2012, 18, 2695-2703.	3.2	237
7	Prognostic relevance of cancer-associated fibroblasts in human cancer. Seminars in Cancer Biology, 2014, 25, 61-68.	4.3	215
8	Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Laboratory Investigation, 2006, 86, 202-211.	1.7	196
9	Prognostic impact of tumourâ€infiltrating B cells and plasma cells in colorectal cancer. International Journal of Cancer, 2016, 139, 1129-1139.	2.3	192
10	The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Letters, 2013, 333, 222-228.	3.2	162
11	Multispectral imaging for quantitative and compartmentâ€specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. Journal of Pathology, 2018, 244, 421-431.	2.1	159
12	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Modern Pathology, 2017, 30, 1411-1421.	2.9	151
13	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 1217-1233.	1.5	137
14	Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. Nature Biomedical Engineering, 2017, 1, 796-806.	11.6	131
15	Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer, 2019, 130, 50-58.	0.9	127
16	Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. Cancer Research, 2021, 81, 956-967.	0.4	104
17	Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer. Cancer Research, 2010, 70, 2644-2654.	0.4	84
18	Impact of Thawing on RNA Integrity and Gene Expression Analysis in Fresh Frozen Tissue. Diagnostic Molecular Pathology, 2009, 18, 44-52.	2.1	83

#	Article	IF	Citations
19	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in nonâ€small ell lung cancer. International Journal of Cancer, 2014, 135, 2206-2214.	2.3	82
20	Profiling cancer testis antigens in non–small-cell lung cancer. JCI Insight, 2016, 1, e86837.	2.3	82
21	An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4660-4672.	3.2	81
22	Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biology, 2011, 12, R108.	13.9	79
23	Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. Journal of Ovarian Research, 2016, 9, 21.	1.3	76
24	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	15.2	75
25	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. Journal of Thoracic Oncology, 2016, 11, 862-872.	0.5	70
26	The Role of TGF- $\hat{l}^2$ Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 3611.	1.8	66
27	The clinical impact of tumourâ€infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study. International Journal of Cancer, 2017, 141, 1654-1666.	2.3	65
28	Expression of scavenger receptor <scp>MARCO</scp> defines a targetable tumorâ€associated macrophage subset in nonâ€small cell lung cancer. International Journal of Cancer, 2018, 143, 1741-1752.	2.3	65
29	Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 848-859.	0.6	64
30	CD99 is a novel prognostic stromal marker in nonâ€small cell lung cancer. International Journal of Cancer, 2012, 131, 2264-2273.	2.3	63
31	In Situ Identification of Genes Regulated Specifically in Fibroblasts of Human Basal Cell Carcinoma. Journal of Investigative Dermatology, 2007, 127, 1516-1523.	0.3	55
32	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal of Thoracic Oncology, 2019, 14, 628-640.	0.5	54
33	The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget, 2017, 8, 72108-72126.	0.8	53
34	Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS ONE, 2017, 12, e0187246.	1.1	51
35	Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1833-1840.	0.5	50
36	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle. Journal of Nuclear Medicine, 2018, 59, 1092-1098.	2.8	48

#	Article	IF	Citations
37	Laser-Assisted Cell Microdissection Using the PALM System. , 2005, 293, 151-166.		46
38	Identification of sample annotation errors in gene expression datasets. Archives of Toxicology, 2015, 89, 2265-2272.	1.9	46
39	Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy. PLoS ONE, 2016, 11, e0167585.	1.1	44
40	Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. Journal of Thoracic Oncology, 2017, 12, 1257-1267.	0.5	43
41	In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. Oncotarget, 2013, 4, 2407-2418.	0.8	42
42	LIPGâ€promoted lipid storage mediates adaptation to oxidative stress in breast cancer. International Journal of Cancer, 2019, 145, 901-915.	2.3	41
43	Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. Human Pathology, 2019, 84, 221-230.	1.1	39
44	Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. International Journal of Cancer, 2020, 146, 3461-3473.	2.3	39
45	Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. Archives of Pathology and Laboratory Medicine, 2020, 144, 1075-1085.	1.2	38
46	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer, 2015, 15, 125.	1.1	35
47	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer, 2016, 16, 603.	1.1	33
48	Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. International Journal of Cancer, 2013, 132, 2020-2031.	2.3	32
49	RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. Genes and Development, 2017, 31, 2099-2112.	2.7	32
50	NK―and T ell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti TLAâ€4 therapy. International Journal of Cancer, 2019, 145, 2238-2248.	2.3	31
51	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740.	0.4	29
52	Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression. Cancer Letters, 2015, 356, 837-845.	3.2	28
53	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. Lung Cancer, 2021, 155, 10-19.	0.9	28
54	LRIG1 is a prognostic biomarker in non-small cell lung cancer. Acta Oncológica, 2015, 54, 1113-1119.	0.8	27

#	Article	IF	Citations
55	Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. American Journal of Clinical Pathology, 2018, 150, 533-544.	0.4	27
56	Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non–Small Cell Lung Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 648-659.	0.6	26
57	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. Cell Death and Differentiation, 2021, 28, 1477-1492.	5.0	26
58	Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC. Molecular Cancer Research, 2017, 15, 1354-1365.	1.5	25
59	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269.	2.7	25
60	Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History. Clinical Cancer Research, 2014, 20, 4912-4924.	3.2	24
61	Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray. Clinical Lung Cancer, 2019, 20, 258-262.e1.	1.1	23
62	Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status. PLoS ONE, 2013, 8, e78614.	1.1	23
63	Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome. Anticancer Research, 2015, 35, 3979-85.	0.5	23
64	c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. Lung Cancer, 2019, 133, 69-74.	0.9	22
65	An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1–Positive Lung Adenocarcinomas. Journal of Thoracic Oncology, 2018, 13, 1676-1691.	0.5	21
66	Quantification of Normal Cell Fraction and Copy Number Neutral LOH in Clinical Lung Cancer Samples Using SNP Array Data. PLoS ONE, 2009, 4, e6057.	1.1	21
67	COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer. Acta Oncológica, 2018, 57, 244-250.	0.8	20
68	Platelet-derived growth factor receptor $\hat{l}^2$ activation and regulation in murine myelofibrosis. Haematologica, 2020, 105, 2083-2094.	1.7	20
69	FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. European Journal of Cancer, 2021, 151, 136-149.	1.3	20
70	Transcriptome analysis of periodontitis-associated fibroblasts by CAGE sequencing identified DLX5 and RUNX2 long variant as novel regulators involved in periodontitis. Scientific Reports, 2016, 6, 33666.	1.6	18
71	Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periampullary Adenocarcinoma. Frontiers in Immunology, 2020, 11, 558169.	2.2	18
72	Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology, 2012, 61, 744-748.	1.6	17

#	Article	IF	CITATIONS
73	Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Modern Pathology, 2017, 30, 964-977.	2.9	17
74	LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease. Lung Cancer, 2018, 125, 174-184.	0.9	17
75	An integrative transcriptome analysis reveals a functional role for thyroid transcription factorâ€1 in small cell lung cancer. Journal of Pathology, 2018, 246, 154-165.	2.1	17
76	A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Scientific Reports, 2019, 9, 5207.	1.6	17
77	Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. Lung Cancer, 2021, 151, 53-59.	0.9	17
78	Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. Cancers, 2021, 13, 3116.	1.7	17
79	Infiltration of NK and plasma cells is associated with a distinct immune subset in nonâ€small cell lung cancer. Journal of Pathology, 2021, 255, 243-256.	2.1	17
80	The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling. Oncotarget, 2016, 7, 1120-1143.	0.8	17
81	HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples. Journal of Molecular Diagnostics, 2015, 17, 729-739.	1.2	16
82	Fibroblast <scp>VEGF</scp> â€receptor 1 expression as molecular target in periodontitis. Journal of Clinical Periodontology, 2016, 43, 128-137.	2.3	16
83	Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer. Lung Cancer, 2018, 125, 157-163.	0.9	16
84	An integrative proteomics method identifies a regulator of translation during stem cell maintenance and differentiation. Nature Communications, 2021, 12, 6558.	<b>5.</b> 8	16
85	A novel strategy based on histological protein profiling <i>inâ€silico</i> for identifying potential biomarkers in urinary bladder cancer. BJU International, 2009, 104, 1780-1785.	1.3	14
86	An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non–small-cell lung cancer. European Journal of Cancer, 2020, 132, 24-34.	1.3	14
87	PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung. Cancer Immunology, Immunotherapy, 2021, 70, 2577-2587.	2.0	14
88	The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545.	1.7	14
89	Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 186-193.	2.0	11
90	Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Scientific Reports, 2019, 9, 1319.	1.6	11

#	Article	IF	CITATIONS
91	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS ONE, 2020, 15, e0243900.	1.1	11
92	Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung. BMC Cancer, 2019, 19, 741.	1.1	10
93	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in nonâ€small cell lung cancer. Cancer Medicine, 2020, 9, 5609-5619.	1.3	10
94	Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection. Viruses, 2021, 13, 2456.	1.5	10
95	ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. Cancer Letters, 2020, 489, 121-132.	3.2	8
96	Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines. Journal of Clinical Pathology, 2022, 75, 302-309.	1.0	7
97	Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern. Cancers, 2022, 14, 689.	1.7	7
98	Regulation of tyrosine phosphatases in the adventitia during vascular remodelling. Biochemical and Biophysical Research Communications, 2009, 382, 678-684.	1.0	6
99	Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. European Journal of Cancer, 2022, 168, 128-137.	1.3	6
100	TGF-β-mediated epithelial–mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma. Scientific Reports, 2021, 11, 22380.	1.6	5
101	The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model. Frontiers in Oncology, 2020, 10, 1717.	1.3	4
102	Targeting hepatocyte growth factor in epithelial $\hat{a} \in \text{``stromal'}$ interactions in an in vitro experimental model of human periodontitis. Odontology / the Society of the Nippon Dental University, 2021, 109, 912-920.	0.9	3
103	Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 2022, 31, 100556.	0.7	3
104	Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma. Frontiers in Oncology, 2022, 12, 873532.	1.3	3
105	High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC. Cancers, 2021, 13, 3151.	1.7	2
106	Programmed Cell Death Ligand 1 Expression in Resected Non–Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562.	1.1	1
107	PD-L1 immunohistochemistry in clinical diagnostics: Inter-pathologist variability is as high as assay variability Journal of Clinical Oncology, 2017, 35, e20637-e20637.	0.8	1
108	Prognostic impact of tumor-associated B-cells and plasma cells in esophageal and gastric adenocarcinoma Journal of Clinical Oncology, 2016, 34, 63-63.	0.8	0